Acupuncture plus topiramate placebo versus topiramate plus sham acupuncture for the preventive treatment of chronic migraine: A single-blind, double-dummy, randomized controlled trial

Lu Liu,Qiuyi Chen,Luopeng Zhao,Tianli Lyu,Limin Nie,Quan Miao,Yuhan Liu,Libin Zheng,Feiyu Fu,Yuxi Luo,Chenxi Zeng,Chengcheng Zhang,Peiyue Peng,Yixin Zhang,Bin Li
DOI: https://doi.org/10.1177/03331024241261080
2024-06-13
Cephalalgia
Abstract:Cephalalgia, Volume 44, Issue 6, June 2024. BackgroundAcupuncture has been used for the treatment of chronic migraine, but high-quality evidence is scarce. We aimed to evaluate acupuncture's efficacy and safety compared to topiramate for chronic migraine.MethodsThis double-dummy randomized controlled trial included participants aged 18–65 years diagnosed with chronic migraine. They were randomly assigned (1:1) to receive acupuncture (three sessions/week) plus topiramate placebo (acupuncture group) or topiramate (50–100 mg/day) plus sham acupuncture (topiramate group) over 12 weeks, with the primary outcome being the mean change in monthly migraine days during weeks 1–12.ResultsOf 123 screened patients, 60 (mean age 45.8, 81.7% female) were randomly assigned to acupuncture or topiramate groups. Acupuncture demonstrated significantly greater reductions in monthly migraine days than topiramate (weeks 1–12: −2.79 [95% CI: −4.65 to −0.94, p = 0.004]; weeks 13–24: −3.25 [95% CI: −5.57 to −0.92, p = 0.007]). No severe adverse events were reported.ConclusionsAcupuncture may be safe and effective for treating chronic migraine. The efficacy of 12 weeks of acupuncture was sustained for 24 weeks and superior to that of topiramate. Acupuncture can be used as an optional preventive therapy for chronic migraine.Trial registrationISRCTN.org Identifier 13563102.
neurosciences,clinical neurology
What problem does this paper attempt to address?